Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
miércoles, 29 de diciembre de 2010
The influence of family history on prostate cancer... [BJU Int. 2010] - PubMed result
BJU Int. 2010 Dec 16. doi: 10.1111/j.1464-410X.2010.10024.x. [Epub ahead of print]
The influence of family history on prostate cancer risk: implications for clinical management.
Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schröder FH, Tubaro A.
Department of Urology and Andrology, Danube Hospital, Vienna, Austria Department of Urology, Hospital Clinic Department of Urology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain Division of Surgery and Interventional Science, University College London (UCL) Hospitals NHS Foundation Trust/UCL Comprehensive Biomedical Research Centre, London, UK Department of Urology, Academic Hospital, Braunschweig, Germany Department of Urology and Andrology, Hospital St. John of God, Vienna, Austria Department of Urology, Erasmus Medical Center, University Medical Centre, Rotterdam, The Netherlands Department of Urology, Sant'Andrea Hospital 2nd School of Medicine, 'La Sapienza' University of Rome, Rome, Italy.
Abstract
• The most recent evidence for the link between a family history of prostate cancer and individual risk for future disease was examined, with the aim of understanding what the existence and nature of a family history of prostate cancer does to a man's risk of developing the disease. • Our findings highlighted the clear association between a family history of prostate cancer and increased risk of developing the disease; with a greater proximity of relatedness, greater number of family members affected and/or earlier age at diagnosis of the family member elevating risk further. • These findings have important clinical implications for the identification and subsequent management of men deemed to be at increased risk of developing prostate cancer. The evidence for prostate cancer risk reduction with the mono 5α-reductase inhibitor (5ARI) finasteride in a low-risk population and, more recently, with the dual 5ARI dutasteride in a population at increased risk of developing the disease, has potential to expand management options for men at risk of developing prostate cancer beyond more frequent and/or earlier surveillance. • Given that family history can be easily assessed in routine clinical practice, it should be regarded as an important parameter to consider alongside PSA level for prostate cancer risk assessment.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
PMID: 21166744 [PubMed - as supplied by publisher]
The influence of family history on prostate cancer... [BJU Int. 2010] - PubMed result
No hay comentarios:
Publicar un comentario